This retrospective study demonstrates that the obesity paradox applies to patients receiving CAR T-cell therapy and that sarcopenia can exert long-lasting adverse effects on treatment responses. The data highlight use of immuno-nutritional scores could aid in patient risk-stratification.

The authors report regional diversity in the distribution of breast cancer subtypes and immune cell composition in sub-Saharan Africa (SSA) that was associated with a higher prevalence of nonimmunogenic breast cancer phenotypes in Western SSA.

Immune-inflamed cancers can be responsive to immunotherapies; however, their granular characterization is challenging. iBRIDGE integrates and ‘bridges’ bulk and scRNA-seq datasets and can be used to identify cell-type specific markers of immune-inflamed tumors in multiple tumor cohorts.

Identification of tumor-specific antigens is crucial for developing effective cancer treatments. The authors use de novo MS and proteogenomics to generate an atlas of non-canonical MHC class I–associated peptides, providing potential targets for T-cell therapies or vaccines.

The authors show that adding an extended half-life IL2 to anti–PD-1 has a beneficial effect in the treatment of a murine glioblastoma model. The data provide rationale for evaluating this combination in the clinic.

The authors show that IL1β blockade enhances the effectiveness of anticancer treatments docetaxel and anti–PD-1 in several mouse models of cancer; this effect appears to be mediated by changes in the tumor microenvironment

The authors show T cells expressing a modified IgG receptor and a signaling coreceptor efficiently mediate potent antitumor immunity without on-target, off-tumor activity, suggesting a way to address challenges of CAR T-cell therapy for solid tumors.

Patient-derived triple-negative BCSCs are shown to be efficiently recognized and killed by γδ T cells, but xenografted BCSCs evade immune recognition by γδ T cells by various mechanisms, paving the way for novel combinatorial immunotherapies for TNBC.

EBV-associated NPC often escapes immune surveillance by NK cells. The authors find that EBV-induced expression of B7-H3 in NPC cells mediates evasion of NK cells, providing a new target for enhancing NK cell–based immunotherapy for EBVassociated NPC.

The tumor-infiltrating T-cell repertoire can be used to characterize effective antitumor responses. Here, the expansion of diverse tumor-reactive clones via clonal spreading is demonstrated to be a characteristic of T-cell responses induced by anti-CD4 and anti–PD-L1 treatments.